KALA BIO, Inc. KALA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
-258.66
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $0 | -$27.0M | — | — | $7.0M |
| 2024 | $0 | -$38.5M | — | — | $12.3M |
| 2023 | $0 | -$42.2M | — | — | $7.5M |
| 2022 | $3.9M | -$44.8M | — | — | $19.0M |
| 2021 | $11.2M | -$142.6M | — | — | $16.8M |
| 2020 | $6.4M | -$104.3M | — | — | $100.0M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER | 2025-10-23 | Sell | 967 | $0.82 |
| Iwicki Mark T | director | 2025-10-23 | Sell | 154,894 | $0.81 |
| Bazemore Todd | director | 2025-10-22 | Sell | 47,768 | $0.83 |
| Brazzell Romulus K | SEE REMARKS | 2025-10-22 | Sell | 46,748 | $0.83 |
| Kharabi Darius | CHIEF BUSINESS OFFICER | 2025-10-22 | Sell | 20,806 | $0.83 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | 2025-10-22 | Sell | 32,230 | $0.83 |
| BAKER BROS. ADVISORS LP | 2025-10-01 | Sell | 50,640 | $1.38 | |
| BAKER BROS. ADVISORS LP | 2025-10-01 | Sell | 462,967 | $1.38 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -258.66 (distress)
- Working capital / assets 0.737
- Retained earnings / assets -73.224
- EBIT / assets -4.127
- Equity / liabilities 2.805
Source: SEC EDGAR filings · CIK 0001479419 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.